NCT03212404 2025-02-03
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Phase 1 Active not recruiting
Checkpoint Therapeutics, Inc.
Pfizer
Juno Therapeutics, a Subsidiary of Celgene
Blueprint Medicines Corporation
Novartis